Ciprostene是新合成的PGI_2衍生物,与前列环素相比,本品化学性质稳定。初步临床试验证实,短时间(20～30分钟)以1280ng/kg/min速度静脉滴注ciprostene对腺二磷(ADP)所致血小板聚集作用产生剂量依赖性抑制作用。但体外和体内试验测得本品的作用强度仅为前列环素的1/100,显然有必要延长持续输注给药时间以获得满意的疗 Ciprostene is a newly synthesized PGI 2 derivative, which is chemically stable compared to prostacyclin. Preliminary clinical trials confirmed that short-term (20 to 30 minutes) intravenous infusion of ciprostene at a rate of 1280 ng / kg / min produced a dose-dependent inhibition of ADP-induced platelet aggregation. However, in vitro and in vivo tests measured the strength of this product is only 1/100 of prostacyclin, it is clearly necessary to extend the duration of infusion administration in order to obtain satisfactory treatment